Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.7%

6 terminated/withdrawn out of 29 trials

Success Rate

77.8%

-8.7% vs industry average

Late-Stage Pipeline

3%

1 trials in Phase 3/4

Results Transparency

67%

14 of 21 completed trials have results

Key Signals

14 with results

Enrollment Performance

Analytics

Phase 1
17(58.6%)
Phase 2
11(37.9%)
Phase 3
1(3.4%)
29Total
Phase 1(17)
Phase 2(11)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (29)

Showing 20 of 29 trials
NCT03119064Phase 1Terminated

BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma

Role: collaborator

NCT02387216Phase 2Terminated

A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC

Role: collaborator

NCT02399137Phase 2Completed

A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer

Role: lead

NCT01520389Phase 1Completed

Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

Role: lead

NCT03076372Phase 1Unknown

A Study Evaluating MM-310 in Patients With Solid Tumors

Role: lead

NCT02538627Phase 1Terminated

Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib

Role: lead

NCT01774851Phase 2Terminated

A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

Role: lead

NCT02640365Phase 1Completed

A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer

Role: collaborator

NCT02785068Phase 1Withdrawn

Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer

Role: lead

NCT02213744Phase 2Terminated

MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients

Role: lead

NCT01304797Phase 1Unknown

Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer

Role: lead

NCT01447225Phase 1Completed

Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors

Role: lead

NCT01209195Phase 1Completed

A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers

Role: lead

NCT01451632Phase 1Completed

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

Role: lead

NCT00734305Phase 1Completed

Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

Role: lead

NCT00994123Phase 1Completed

A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Role: lead

NCT01733004Phase 1Completed

A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors

Role: lead

NCT01494506Phase 3Completed

Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer

Role: lead

NCT01151046Phase 2Completed

Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

Role: lead

NCT01447706Phase 2Completed

A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers

Role: lead